Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Items 401–477 of 477
New Therapies in Hepatitis C Virus and Chronic Liver Disease: Antifibrotics
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.019 · Cited by 7
Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update
Stasi, C., & Mega, A. (2025) · Life · doi:10.3390/life15111682 · Cited by 7
“Miyahara et al. [32] evaluated the ability of PPAR to activate HSC of rats from cholestatic liver fibrosis induced by bile duct ligation.”
Identification of liver X receptor and farnesoid X receptor dual agonists from Tithonia diversifolia
Lin, H. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0359-5 · Cited by 7
“Apart from PPAR-k, LXR and FXR are two other NRs exhibiting antihyperglycemic and hepatoprotective effects (Miyahara et al., 2000).”
Molecular and Cellular Aspects of Cirrhosis and How an Adenosine Derivative Could Revert Fibrosis
Rodríguez‐Aguilera, J. R., de Vaca, R. P., Guerrero‐Celis, N., Velasco-Loyden, G., Domínguez-López, M., Targa, F. R., & de Sánchez, V. C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83481 · Cited by 5
“PPARγ is expressed in quiescent HSC, and its expression is rapidly decreased during HSC activation in vitro and in vivo [68].”
BackgroundLysine 222 in PPAR γ1 functions as the key site of MuRF2-mediated ubiquitination modification
Fan, Y., Xu, F., Wang, R., & He, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-28905-5 · Cited by 5
Cheng, Y., Zhu, X., Cheng, F., Li, J., & Zhou, Y. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.050 · Cited by 7
Gandhi, C. R. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_5 · Cited by 6
Boretto, C., Muzio, G., & Autelli, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117461 · Cited by 4
“For these experiments we selected GW9662, an irreversible PPAR γ inhibitor [30].”
Récepteurs nucléaires PPAR et hépatologie : implications physiopathologiques et thérapeutiques
Dharancy, S., Louvet, A., Hollebecque, A., Desreumaux, P., Mathurin, P., & Dubuquoy, L. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2008.01.029 · Cited by 5
“[24] Miyahara T, Schrum L, Rippe R, Xiong S, Yee Jr HF, Motomura K, et al.”
BackgroundSerum Adiponectin, a Novel Biomarker Correlates with Skin Thickness in Systemic Sclerosis
Leodori, G., Pellicano, C., Basile, V., Colalillo, A., Navarini, L., Gigante, A., Gulli, F., Marino, M., Basile, U., & Rosato, E. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101737 · Cited by 4
PPARγ induces the paroxysm of endometriosis by regulating the transcription of MAT2A gene.
Zhang, S., Zhuang, L., Liu, Q., Yu, X., Min, Q., Chen, M., & Chen, Q. (2021) · American Journal of Translational Research · Cited by 4
Cell Biology of NASH: Fibrosis and Cell Proliferation
Leclercq, I. A., & Horsmans, Y. (2004) · Wiley eBooks · doi:10.1002/9780470987438.ch12 · Cited by 4
Promising role of peroxisome proliferator-activated receptors in respiratory disorders, a review
Beigoli, S., Kiani, S., Asgharzadeh, F., Memarzia, A., & Boskabady, M. H. (2024) · Drug Metabolism Reviews · doi:10.1080/03602532.2024.2442012 · Cited by 3
“…it is a key step in liver fibrosis for hepatic stellate cells to differentiate into myofibroblasts (Bissell 1990; Hautekeete and Geerts 1997; Miyahara et al. 2000). when activated by platelet-derived growth factor (PDGF), PPARγ agonists inhibit the proliferation of hepatic stellate cells…”
Islam, M. A., Mawya, J., Salma, U., Kasim, N. H. A., & Haque, N. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i11.111090 · Cited by 4
Fibrose hépatique : de la physiopathologie aux implications thérapeutiques
Mallat, A., & Lotersztajn, S. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.05.004 · Cited by 4
Cellular and Molecular Mechanism of Liver Fibrosis: A Critical Insight
Parida, G. R., Pattnaik, G., & Behera, A. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.01066 · Cited by 3
Expression of the Peroxisome Proliferator-Activated Receptors (PPARs) in the Hepatic Stellate Cells
Sato, T., Sato, M., Miura, M., Higashi, N., Wang, D., Suzuki, S., Imai, K., Kojima, N., & Senoo, H. (2004) · Comparative Hepatology · doi:10.1186/1476-5926-2-s1-s17 · Cited by 3
“Several reports [3-5] have suggested that expression of PPARgamma was reduced with the acquisition of activated phenotype (termed as "activation") such as lack of cytoplasmic lipid droplets containing vitamin A in subcultured HSC.”
BackgroundCharacterization of the human zinc finger protein 267 promoter: Essential role of nuclear factor Y
Hu, K., Fink, M., Froh, M., Gäbele, E., Hellerbrand, C., Mühlbauer, M., Wiest, R., Schölmerich, J., & Schnabl, B. (2005) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2005.03.001 · Cited by 3
“Several transcription factors are involved in the activation process of HSCs including AP-1 [4,5] ,N FnB [6,7], CCAAT/enhancer-binding proteins (C/ EBP) [8,9] ,P PARg [ 10 ,11], nuclear factor Y (NF-Y, also named CBF for CCAAT binding factor) [12], and members of the Kruppel-like zinc finger family, such as Kruppel-li…”
BackgroundBundschuh, J., Neumann, M., Zimny, S., Spirk, M., & Buechler, C. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.113896 · Cited by 2
Reduction in Obesity-Related Hepatic Fibrosis by SR1664
McVicker, B. L., Simpson, R. L., Hamel, F. G., & Bennett, R. G. (2023) · Biology · doi:10.3390/biology12101287 · Cited by 3
“Despite early studies showing that the full PPAR γ thiazolidinedione agonists could inhibit HSC activation in vitro [7,16,17] and prevent hepatic fibrosis in some rodent models [7–9, 18, 19] , As mentioned earlier, full agonists of PPAR γ activate a strong adipogenic transcriptional program that can…”
BackgroundYoo, S.-H., Yoon, C.-J., Kim, D.-H., Yum, M. J., Kim, J.-S., Yoon, Y.-C., Chun, C.-S., Lee, J.-D., Koppula, S., & Song, M. (2015) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v14i8.13 · Cited by 3
“The most intriguing aspect of the involvement of HSCs in liver fibrogenesis is that they undergo phenotypic changes often characterized as myofibroblastic activation [7].”
BackgroundTissue Distribution and Versatile Functions of PPARs
Youssef, J., & Badr, M. Z. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-420-3_5 · Cited by 5
Peroxisome Proliferator-Activated Receptor γ and Hepatic Stellate Cell Activation
Miyahara, T., Hazra, S., Xiong, S., Motomura, K., She, H., & Tsukamoto, H. (2003) · Elsevier eBooks · doi:10.1016/b978-012525251-5/50011-7 · Cited by 2
Self-citationNeuschwander‐Tetri, B. A. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50060-7 · Cited by 2
Tsukamoto, H. (2002) · Hepatology · doi:10.1002/hep.510360430 · Cited by 2
Self-citationNon-Alcoholic Fatty Liver Disease : A clinical and histopathological study
Ekstedt, M. (2008) · DiVA (Linkoping University) · Cited by 3
Friedman, S. L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.013 · Cited by 2
Ding, Y., Tao, C., Chen, Q., Chen, L., Hu, X., Li, M., Wang, S., & Jiang, F. (2022) · Open Chemistry · doi:10.1515/chem-2022-0192 · Cited by 1
Marra, F., Galastri, S., Aleffi, S., & Pinzani, M. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_3 · Cited by 3
Choi, H.-J., & Soh, Y. (2007) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2007.15.4.261 · Cited by 1
“In previous report, PPAR-γ agonists decreased the synthesis of collagen (Miyahara et al., 2000).”
BackgroundBilzer, M., & Gerbes, A. L. (2002) · Hepatology · doi:10.1002/hep.510360429 · Cited by 1
ADVANCES IN TRANSLATIONAL SCIENCE
Sellin, J. H., Murthy, S. K., Goetz, M., Hoffman, A. W., & Kießlich, R. (2012) · Cited by 1
Pinzani, M., & Marra, F. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_3 · Cited by 1
Yu, Q., Koda, S., Xu, N., Li, J., Wang, J.-L., Liu, M., Liu, J., Zhang, Y., Yang, H.-M., Zhang, B., et al. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230418111949 · Cited by 1
Pizaño, M. Y. M., Llanos-Angulo, L. A. G., Ventura‐Juárez, J., Quintanar‐Stephano, A., Cárdenas, O. S., Montes‐de‐Oca‐Luna, R., Loera‐Arias, M. D. J., & Muñoz‐Ortega, M. H. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123859 · Cited by 1
Peut-on traiter la stéatohépatite métabolique ?
Ratziu, V., Vispo, M., Tahiri, M., Bonyhay, L., de Torres, M., Bernhardt, C., Poynard, T., & Lebray, P. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89386-9 · Cited by 1
“L’administration des agonistes de PPARgamma contribue à maintenir le phénotype quiescent des CEF [67, 68].”
BackgroundInfluentialNON INVASIVE EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND C
Ashraf, S. (2009) · HEC National Digital Library · Cited by 1
Ohata, M., Suzuki, H., Sakamoto, K., Hashimoto, K., Nakajima, H., Yamauchi, M., Hokkyo, K., Yamada, H., & Toda, G. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2004.tb03232.x · Cited by 4
Li, J. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Challa, A. A. (2011) · DigiNole (Florida State University)
TARGETED THERAPY FOR LIVER FIBROSIS AND CANCER
Zhang, Y. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
Ferrer, A. P. (2005) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Non-alcoholic fatty liver disease: an emerging liver disease
Söderberg, C. (2011) · Figshare
Activation of Hepatic Stellate Cells: Anti-Adipogenic Differentiation?
Tsukamoto, H. (2006) · Springer eBooks · doi:10.1007/4-431-27174-0_20
“quiescent HSC express peroxisome proliferator-activated receptor g (PPARg), a key transcription factor for adipocyte differentiation [17], and this nuclear receptor is depleted in activated HSC in vitro [17,18] and in vivo [17].”
BackgroundSelf-citationRole of membrane associated molecules in liver fibrosis
Rosenberg, P. M. (2008) · Figshare
Cellular and molecular basis of fibrogenesis in NASH
Marra, F., Bertolani, C., Aleffi, S., Provenzano, A., & Vizzutti, F. (2010) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2009.12.001
Molecular and Cellular Aspects of Liver Fibrosis
Kawada, N. (2005) · Springer eBooks · doi:10.1007/0-387-26476-0_10
The Effect of Resveratrol on Bone Status in Rats with Bile Duct Obstruction
Živná, H., Mičuda, S., Doleželová, E., & Živný, P. (2013) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2013.31007
“The involved mechanism is complex and it seems that with respect to lean and fat tissues it includes also preventive effect of resveratrol on bile duct ligation-mediated activation of hepatic stellate cells, in which BDO leads to reduced PPAR gamma expression [23] associated with activated leptin production, suppresse…”
BackgroundPPARα activation in portal hypertension
Liu, H., Lee, S. S., Groszmann, R. J., Iwakiri, Y., & Taddei, T. H. (2012) · Hepatology · doi:10.1002/hep.26045
“The consensus view is that PPARa is not expressed in quiescent or activated HSCs and has not been shown to affect HSC biology in vitro or hepatic fibrosis.(13) However, not all studies agree with this notion: Ip et al.”
BackgroundInhibition of leptin receptors through plant-derived ligands for liver fibrosis drug development
Chakraborty, C., Banerjee, S., Banerjee, K., Hsu, M. J., & Agoramoorthy, G. (2012) · Asian Biomedicine · doi:10.5372/1905-7415.0604.085
“During HSC activation, expression of PPAR γ decreases to almost undetectable level and are expressed when exposed to PPAR γ agonists [41-44].”
BackgroundAngiotensin Converting Enzyme in the Pathophysiology of Liver Fibrosis
Wei, Y. H. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-4483-6_8
Using Stem Cells to Promote Wound Healing: An Emerging Solution for a Clinical Problem
Foster, A. D., & Davis, T. A. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21702-4_8
Avaliação da atividade da frutose-1,6-bisfosfato em células GRX expostas a ferro livre
Dias, H. B. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Hepatic stellate cell transdifferentiation: Pro-fibrogenic effectors
Lakner, A. M., & NC DOCKS at The University of North Carolina at Charlotte (2011) · NC Digital Online Collection of Knowledge and Scholarship (The University of North Carolina at Greensboro)
Li, J., & Yin, Z. (2010) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2010.01017
Adachi, M., Osawa, Y., Uchinami, H., Kitamura, T., Accili, D., & Brenner, D. A. (2007)
Therapeutic Role of Peroxisome Proliferator-Activated Receptors Gamma in the Treatment of Fibrosis
Tripathi, G. M., & Gupta, S. (2016) · International Journal of Biomedical Research · doi:10.7439/ijbr.v7i6.3390
“quiescent, lipid storing form [49].”
Tissue Repair and Cancer Control through PPARs and Their Coregulators
Michalik, L., & Wahli, W. (2008) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812819178_0013
Friedman, S. L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.004
Amirinejad, A., Totmaj, A. S., Mardali, F., Hekmatdoost, A., Emamat, H., Safa, M., & Shidfar, F. (2021) · Research Square · doi:10.21203/rs.3.rs-492861/v1
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00010-x
Wang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15047593
Wang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15047590
Wang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15047596
Wang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.15047599
MECHANISMS OF LIVER DAMAGE IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION
Iancu, A.-M., & Sorin, R. (2024) · Romanian Archives of Microbiology and Immunology · doi:10.54044/rami.2024.01.06
Amirinejad, A., Totmaj, A. S., Mardali, F., Hekmatdoost, A., Emamat, H., Safa, M., & Shidfar, F. (2021) · Figshare · doi:10.6084/m9.figshare.16569745
Amirinejad, A., Totmaj, A. S., Mardali, F., Hekmatdoost, A., Emamat, H., Safa, M., & Shidfar, F. (2021) · Figshare · doi:10.6084/m9.figshare.16569748
Hepatic stellate cells in liver fibrosis: From biology to pathology
Esselmani, H., Nadir, Y., Ennadi, R., Zouhairi, N., Hiba, O. E., Lkousse, M. A., Najimi, M., & Merzouki, M. (2025) · Open Veterinary Journal · doi:10.5455/ovj.2025.v15.i12.4
“This altered expression of lipid metabolism regulators highlights the dynamic role of HSCs in liver metabolism, where their function shifts from fat storage to fibrosis and tissue remodeling upon activation (Miyahara et al. , 2000).”
Étude mécanistique de la fibrose interstitielle rénale et essai de preuve de concept thérapeutique
Gaillard, F. (2018) · theses.fr (ABES) · doi:10.70675/72e11c14zcc9fz4acdzbb83z2368f5351848 · Cited by 1
Potentiel thérapeutique de l'activation du récepteur nucléaire PPARgamma dans la myélofibrose
Lambert, J. (2019) · theses.fr (ABES) · doi:10.70675/279070ccze01ez49cdz8d89zd6a3e5c8d1aa
Boudouin, M. (2024) · theses.fr (ABES) · doi:10.70675/08e73893z9659z4928z96cdzbf31632f73ae
Perspectives thérapeutiques de la modulation de PPAR-gamma dans les leucémies aiguës myéloïdes
Zhu, J. (2023) · theses.fr (ABES) · doi:10.70675/8a7b9621z18bez4cf1z9eadzab40e77e9c18 · Cited by 1
Nadir, Y., Esselmani, H., Oukhdouch, A., Nechchadi, H., Ennadi, R., Lkousse, M. A., Farouk, I., Najimi, M., & Merzouki, M. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6030023
“Our findings on the downregulation of FOS may highlight its capacity to impair this process and alleviate LF [34].”
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.